Egyptian Journal of Haematology

Scope & Guideline

Shaping the Landscape of Hematology in the Middle East

Introduction

Welcome to your portal for understanding Egyptian Journal of Haematology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1110-1067
PublisherWOLTERS KLUWER MEDKNOW PUBLICATIONS
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationEGYPT J HAEMATOL / Egypt. J. Haematol.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressWOLTERS KLUWER INDIA PVT LTD, A-202, 2ND FLR, QUBE, C T S NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra 400059, INDIA

Aims and Scopes

The Egyptian Journal of Haematology primarily focuses on advancing the understanding of hematological disorders through clinical and laboratory research. It aims to provide a platform for the dissemination of new research, clinical practices, and innovations in hematology, particularly within the Egyptian context.
  1. Clinical Hematology:
    The journal emphasizes clinical studies that explore the diagnosis, treatment, and management of various hematological conditions, including leukemias, lymphomas, and anemias.
  2. Laboratory Research:
    Research articles often focus on laboratory findings, including genetic, molecular, and immunological studies that contribute to the understanding of hematological diseases.
  3. Transplantation and Cellular Therapy:
    There is a significant focus on hematopoietic stem cell transplantation and its outcomes, including studies on conditioning regimens and post-transplant complications.
  4. Pediatric Hematology:
    The journal features studies specific to pediatric hematology, addressing conditions like sickle cell disease and childhood leukemias, highlighting the unique challenges in managing these populations.
  5. Epidemiological Studies:
    Epidemiological research is a core area, with studies investigating the prevalence and risk factors associated with hematological disorders in the Egyptian population.
  6. Innovative Therapies and Biomarkers:
    The journal promotes research on novel therapies, including immunotherapies and targeted treatments, as well as the identification of biomarkers for diagnosis and prognosis.
The journal has seen an increase in publications addressing contemporary issues in hematology, reflecting current advancements in research and clinical practice. Emerging themes indicate a response to recent global health challenges and innovations in treatment.
  1. COVID-19 Related Hematology Studies:
    Research examining the impact of COVID-19 on hematological patients has surged, exploring complications, treatment responses, and the effects of the pandemic on care delivery.
  2. Genetic and Molecular Studies:
    There is a growing emphasis on the genetic and molecular characterization of hematological diseases, including studies on polymorphisms and gene expressions that influence treatment outcomes.
  3. Immunotherapy and Novel Therapeutic Approaches:
    Increasing interest in immunotherapy for hematological malignancies is evident, with studies focusing on new treatment modalities and their effectiveness in various patient populations.
  4. Quality of Life and Patient-Centered Outcomes:
    Research addressing health-related quality of life in hematology patients, particularly in children, is becoming more prominent, reflecting a holistic approach to patient care.
  5. Biomarkers for Diagnosis and Prognosis:
    The identification and validation of novel biomarkers for the diagnosis and prognosis of hematological disorders are increasingly featured, underscoring the shift towards personalized medicine.

Declining or Waning

While the journal has consistently published a wide range of studies, certain themes appear to be declining in focus. This trend may reflect evolving priorities in hematology research or shifts in clinical practice.
  1. Traditional Hematology Techniques:
    There is a noticeable decrease in studies focused on traditional diagnostic methods, such as basic blood smear analysis, as newer technologies and molecular techniques gain prominence.
  2. General Anemia Studies:
    Research specifically focused on general anemia without a clear link to specific underlying conditions is appearing less frequently, suggesting a shift towards more targeted studies.
  3. Chronic Conditions without Novel Insights:
    Studies on chronic hematological conditions that do not present new treatment insights or understanding are less prevalent, indicating a trend towards more innovative and impactful research.
  4. Single-Center Studies:
    While single-center studies have been a staple, there seems to be a waning interest in these types of publications, with a preference for larger cohort studies or multi-center collaborations that can provide broader insights.

Similar Journals

Blood Cancer Journal

Transforming insights into impactful treatments.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

BLOOD REVIEWS

Fostering innovation in the science of blood.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Blood Science

Navigating the Complexities of Blood Health
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

ANNALS OF HEMATOLOGY

Exploring breakthroughs in blood disorders and treatments.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

Hematologie

Advancing the Science of Blood Disorders
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

CURRENT OPINION IN HEMATOLOGY

Bridging research and application in the realm of hematology.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Hematology Reports

Fostering collaboration in hematological research.
Publisher: MDPIISSN: 2038-8322Frequency: 4 issues/year

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.

Journal of Hematology

Elevating Hematology Through Collaborative Research
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

EXPERIMENTAL HEMATOLOGY

Empowering Discoveries in Blood and Cellular Biology
Publisher: ELSEVIER SCIENCE INCISSN: 0301-472XFrequency: 12 issues/year

EXPERIMENTAL HEMATOLOGY, published by Elsevier Science Inc, is a leading journal in the field of hematology, distinguished by its impactful contributions to the study of blood-related disorders and cellular biology. With an ISSN of 0301-472X and an E-ISSN of 1873-2399, this journal has established a significant presence since its inception in 1973, continuing to be relevant through 2024. It holds a commendable Q1 ranking in Hematology and Q2 in various significant categories including Cancer Research, Cell Biology, Genetics, and Molecular Biology, recognizing its quality and influence in the scientific community. Researchers and professionals can access a wide range of meticulously peer-reviewed articles that promote cutting-edge research and foster collaboration across disciplines. As a vital platform for disseminating innovative findings, EXPERIMENTAL HEMATOLOGY empowers its audience to delve deeper into the complexities of hematological research and brings to light the advances critical for improving patient outcomes.

Indian Journal of Hematology and Blood Transfusion

Bridging Gaps in Blood Science: Research That Matters
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.